Please wait while the formulary information is being retrieved.
NOVACORT (HYDROCORTISONE ACETATE/PRAMOXINE HCL)
- Skin inflammation
- Pruritus ani
2 %-1 % topical gel
- Apply a thin layer to the affected area(s) by topical route 3-4 timesdaily
Pruritus ani
- Apply a thin layer to the affected area(s) by topical route 3 times per day
- Apply a thin layer to the affected area(s) by topical route 4 times per day
- Apply a thin layer to the affected area(s) by topical route 3-4 timesdaily
Skin inflammation
- Apply a thin layer to the affected area(s) by topical route 3 times per day
- Apply a thin layer to the affected area(s) by topical route 4 times per day
- Apply a thin layer to the affected area(s) by topical route 3-4 timesdaily
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Large open wound
Severe
Moderate
- Hypothalamic-pituitary insufficiency
NOVACORT (HYDROCORTISONE ACETATE/PRAMOXINE HCL)
- Skin inflammation
- Pruritus ani
- None
- Erythema
- Stinging of skin
More Frequent
Severe
Less Severe
- Angioedema
- Dermatitis due to topical drug
- Erythema
- Folliculitis
- Pruritus of skin
- Purpura
- Skin and skin structure infection
- Skin atrophy
- Skin rash
- Stinging of skin
- Urticaria
- Headache disorder
- Paresthesia
- Pruritus of skin
- Skin rash
- Telangiectasia
- Treatment site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory insufficiency
- Adrenal cortical insufficiency
- Anaphylaxis
- Bradycardia
- Bullous dermatitis
- Cardiac arrhythmia
- Cataracts
- Central serous chorioretinopathy
- CNS toxicity
- Cyanosis
- Drowsy
- Eyelid edema
- Glaucoma
- Headache disorder
- Hypotension
- Hypothalamic-pituitary insufficiency
- Methemoglobinemia
- Ocular hypertension
- Respiratory depression
- Seizure disorder
- Skin hypopigmentation
- Skin striae
- Skin ulcer
- Tremor
- Unconsciousness
- Urticaria
Less Severe
- Acneiform eruption
- Acute confusion
- Alopecia
- Apprehension
- Blistering skin
- Blurred vision
- Contact dermatitis
- Dizziness
- Dry skin
- Dyschromia
- Edema
- Euphoria
- Glycosuria
- Hirsutism
- Hypercortisolism
- Hyperesthesia
- Hyperglycemia
- Miliaria
- Nervousness
- Perioral dermatitis
- Sensation of cold
- Sensation of warmth
- Skin irritation
- Tinnitus
- Twitching
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Hydrocortisone (Top,Ophth,Rect)
Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
Pediatrics are more sensitive to toxic effects.
- 1 Day – 18 Years
- Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
- 1 Day – 12 Years
- Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
Pramoxine
Prolonged or extensive use may lead to systemic absorption; may affect growth rate.
Pediatrics are more sensitive to toxic effects.
- 1 Day – 18 Years
- Pediatrics are more sensitive to toxic effects.
- 1 Day – 12 Years
- Pediatrics are more sensitive to toxic effects.
Hydrocortisone (topical, Non-systemic)
- Severity Level:
2
- Additional Notes: Systemic absorption unknown; insuff human data
Pramoxine
- Severity Level:
C
- Additional Notes: Insufficient human data
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Hydrocortisone (top., Rectal)
Insufficient data available; limited use may pose little risk
Per briggs, unlikely that significant amounts would be excreted in milk
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | Not known; no or inclusive data | Insufficient data available; limited use may pose little risk |
Pramoxine
Insufficient data available; limited use may pose little risk
Per briggs, unlikely that significant amounts would be excreted in milk
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | Not known; no or inclusive data | Per briggs, unlikely that significant amounts would be excreted in milk |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Pruritus ani | |
| L29.0 | Pruritus ani |
| L29.3 | Anogenital pruritus, unspecified |
| Skin inflammation | |
| L30.8 | Other specified dermatitis |
| L30.9 | Dermatitis, unspecified |
| 0-9 | A-Z |
|---|---|
| L29.0 | Pruritus ani |
| L29.3 | Anogenital pruritus, unspecified |
| L30.8 | Other specified dermatitis |
| L30.9 | Dermatitis, unspecified |
Formulary Reference Tool